Seratrodast




Seratrodast (INN) is a thromboxane A2 (TXA2) receptor (TP receptor) antagonist used primarily in the treatment of asthma. It was the first TP receptor antagonist that was developed as an anti-asthmatic drug and received marketing approval in Japan in 1997. Seratrodast is currently marketed in Japan, China and India (approved in Dec 2012) as an add-on controller therapy in the management of asthma.